Skip to content

A Randomized Controlled Study of Analgesic Pain Relief Lotion for Anal Pain Relief after Hemorrhoidectomy

A Randomized Controlled Study of Analgesic Pain Relief Lotion for Anal Pain Relief after Hemorrhoidectomy

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025001868
Enrollment
Unknown
Registered
2025-09-28
Start date
2025-08-01
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

mixed hemorrhoids

Interventions

Treatment Group:patients receive sitz baths with the "Gangmen Zhitong Xiji".
Placebo Control Group:Patients receive sitz baths with a simulated preparation (placebo) of the "Gangmen Zhitong Xiji".

Sponsors

China-Japan Friendship Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: 1) Meet the diagnostic criteria for hemorrhoids as specified in the Chinese Guidelines for the Diagnosis and Treatment of Hemorrhoidal Diseases (2020) issued by the Colorectal and Anal Surgery Group of the Chinese Society of Surgery, Chinese Medical Association, and satisfy the indications for surgical intervention; 2) Demonstrate good tolerance to surgical procedures involved in this study, such as the Milligan-Morgan hemorrhoidectomy, with no relevant contraindications; 3) Be fully conscious and capable of actively cooperating with the study; 4) Provide fully informed consent signed by both the participant and their family members (following the principles of independent and voluntary signing, with the protocol overseen by the Clinical Research Management and Ethics Committee of China-Japan Friendship Hospital); 5) Age between 18 and 70 years (inclusive).

Exclusion criteria

Exclusion criteria: 1) Patients with systemic diseases such as psychiatric or immune disorders; 2) Patients with severe or uncontrolled infections; 3) Patients with digestive system diseases such as gastritis or gastric ulcers; 4) Patients with malignant tumors; 5) Patients with severe organic diseases of major organs (e.g., heart, liver, or kidneys); 6) Female patients in special physiological periods (e.g., puerperium or pregnancy); 7) Patients with coagulation disorders; 8) Patients with other anorectal diseases; 9) Patients deemed by investigators to have any other factors unsuitable for study participation.

Design outcomes

Primary

MeasureTime frame
VAS score on POD 7;Number of analgesic doses taken;

Secondary

MeasureTime frame
VAS score on POD 1;VAS score on POD 3;VAS score on POD 14;Wound healing rate on postoperative day 1 ;Wound healing rate on postoperative day 7;Wound healing rate on postoperative day 14;Wound healing time ;Wexner score for anal function on postoperative day 14;Assessment of quality of life using the SF-36 questionnaire at postoperative day 14;Blood Pressure;Respiratory Rate;Heart Rate;Temperature;Complete Blood Count ;Liver and Kidney Function Tests;TCM Syndrome Pattern Evaluation;

Countries

China

Contacts

Public ContactLihua Zheng

China-Japan Friendship Hospital

btv126@126.com13366566578

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026